TIDMHCM
RNS Number : 3500B
Hutchison China Meditech Limited
06 June 2019
Disclosure Update
London: Thursday, June 6, 2019: Hutchison China MediTech Limited
("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) today filed the Post
Hearing Information Pack (the "PHIP") with the Stock Exchange of
Hong Kong Limited ("SEHK") in connection with a proposed listing of
its ordinary shares on the Main Board of the SEHK (the "Listing")
and concurrent global offering of ordinary shares (the "Offering")
as previously announced on April 15, 2019. The PHIP contains
unaudited condensed consolidated interim financial information as
of and for the three months ended March 31, 2018 and 2019 and
certain updates regarding the Company's business and financial
information which are available for viewing at
http://www.rns-pdf.londonstockexchange.com/rns/3500B_1-2019-6-6.pdf.
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical
company which researches, develops, manufactures and markets
pharmaceutical products. Its Innovation Platform, Hutchison
MediPharma, has about 420 scientists and staff focusing on
discovering, developing and commercializing targeted therapeutics
and immunotherapies in oncology and autoimmune diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world. Chi-Med's Commercial Platform
manufactures, markets, and distributes prescription drugs and
consumer health products, covering an extensive network of
hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and
the Nasdaq Global Select Market, Chi-Med is headquartered in Hong
Kong and majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med's current expectations regarding future
events. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements.
Factors that may cause such a difference include risks and
uncertainties related to completion of the SEHK's review of
Chi-Med's listing application and completion of the Offering
(including the terms of the Offering), market conditions, the
satisfaction of customary closing conditions related to the
Offering, whether and the degree to which Chi-Med will continue to
benefit from CKHH's support, and Chi-Med's ability to progress the
development of its drug candidates and successfully commercialize
them. More information about the risks and uncertainties faced by
Chi-Med will be contained or incorporated by reference in the
preliminary prospectus filed with the SEHK and preliminary
prospectus supplement filed with the SEC, in each case related to
the Offering, when completed. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. For further
discussion of these and other risks, see Chi-Med's filings with the
SEHK, SEC and on AIM. Chi-Med undertakes no obligation to update or
revise the information contained in this announcement, whether as a
result of new information, future events or circumstances or
otherwise.
Important Notice
This announcement is being issued pursuant to and in accordance
with Rule 135e under the United States Securities Act of 1933, as
amended ("Securities Act"). This announcement does not constitute a
prospectus and does not constitute an offer to sell or the
solicitation of an offer to purchase or acquire, any of the
ordinary shares, American depositary shares or any other securities
of the Company in the United States or any other jurisdiction.
Securities may not be offered or sold in the United States absent
registration or an exemption from registration under the Securities
Act. Any public offering of securities to be made in the United
States will be made by means of a prospectus. Such prospectus may
be obtained from the Company and will contain or incorporate by
reference detailed information about the Company, its management
and financial statements.
No prospectus required for the purposes of the Prospectus
Directive or admission document will be made available in
connection with the matters contained in this announcement. For
these purposes, the term "Prospectus Directive" means Directive
2003/71/EC (including the 2010 PD Amending Directive, to the extent
implemented in the Relevant Member States) and includes any
relevant implementing measure in the Relevant Member State and the
term "2010 PD Amending Directive" means Directive 2010/73/EU.
No money, securities or other consideration is being solicited,
and, if sent in response to the information contained in this
announcement, will not be accepted.
This announcement is not directed to, or intended for
distribution or use by, any person or entity that is a citizen or
resident or located in any locality, state, country or other
jurisdiction where such distribution, publication, availability or
use would be contrary to law or regulation or which would require
any registration or licensing within such jurisdiction.
The distribution of this announcement into jurisdictions other
than the United Kingdom may be restricted by law. Persons into
whose possession this announcement come should inform themselves
about and observe any such restrictions.
In connection with the Offering, the price of the Shares may be
stabilized in accordance with the Securities and Futures (Price
Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong) and
Regulation M under the U.S. Exchange Act of 1934, as amended.
Details of any intended stabilization and how it will be regulated
under the Securities and Futures Ordinance (Chapter 571 of the Laws
of Hong Kong) will be contained in the Company's Hong Kong
prospectus, which will be issued in Hong Kong in connection with
the Hong Kong public offering of the Shares if the Offering
proceeds.
For readers in the European Economic Area
In any European Economic Area Member State that has implemented
the Prospectus Directive, this announcement is only addressed to
and directed at qualified investors in that Member State within the
meaning of the Prospectus Directive. The term "Prospectus
Directive" means Directive 2003/71/EC (and amendments thereto,
including Directive 2010/73/EU, to the extent implemented in each
relevant Member State), together with any relevant implementing
measure in the relevant Member State.
For readers in the United Kingdom
This announcement, insofar as it constitutes an invitation or
inducement to enter into investment activity (within the meaning of
section 21 of the Financial Services and Markets Act 2000, as
amended) in connection with the securities which are the subject of
the potential offering described in this announcement or otherwise,
is being directed only at (i) persons who are outside the United
Kingdom or (ii) persons who have professional experience in matters
relating to investments who fall within Article 19(5) (investment
professionals) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) persons
falling within Article 49(2)(a) to (d) (high net worth companies,
unincorporated associations etc.) of the Order; or (iv) any other
person to whom it may lawfully be communicated (all such persons in
(i) to (iv) together being referred to as "relevant persons"). Any
person who is not a relevant person should not act or rely on this
announcement or any of its contents.
FOR READERS IN THE PEOPLE'S REPUBLIC OF CHINA ("PRC")
This announcement shall not be deemed as public invitation or
inducement to enter into investment activity, nor shall the
publication of this announcement be deemed as offering securities
consultation-related services in the PRC (for the purpose of this
announcement only, excluding Hong Kong, Macau and Taiwan). The
securities which are the subject of the potential offering
described in this announcement may not be offered or sold, and will
not be offered or sold to any person for re-offering or resale,
directly or indirectly, to any resident of the PRC except pursuant
to applicable laws and regulations of the PRC.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@soleburytrout.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@soleburytrout.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
- Zhou Yi, Brunswick +852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 136 7179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDGMGGVKVNGLZG
(END) Dow Jones Newswires
June 06, 2019 02:01 ET (06:01 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024